Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Pulmonology
•
Diffuse Parenchymal Lung Disease
•
IPF
What are the next steps in the management of a patient admitted with an IPF exacerbation resistant to steroid therapy?
Related Questions
Do you consider administration of nintedanib or pirfenidone via enteral tube in patients unable to take PO due to recurrent aspiration?
Do you ever consider close clinical monitoring over antifibrotic therapy in patients ascribed an MDD diagnosis of IPF who have normal lung function and are asymptomatic?
Is there an age at which you consider not starting antifibrotic therapy in a patient with IPF?
Do you consider immunosuppressive agents in progressive interstitial pneumonias or pneumonitis without a clear driving etiology?
What is your preferred steroid sparing agent in the treatment of Sjögren associated LIP?
How do you approach patients with RA and severe bronchiectasis with associated findings of UIP?
Does your approach to treating latent tuberculosis differ in a patient on anti-fibrotic therapy?
Do you perform routine interval screening for pulmonary fibrosis in individuals who have been identified through genetic testing as being at risk for developing pulmonary fibrosis but don't exhibit any signs or symptoms?
Do you ever consider tapering off steroid-sparing agents in patients with stable non-IPF ILD?
Would you restart sirolimus for a decline in lung function or pneumothoraces in a pregnant patient with LAM?
